Labiotech.eu

News and Trends 9 Aug 2022

Pfizer and Valneva to start phase 3 Lyme disease vaccine study

Pfizer Inc. and Valneva SE have initiated a phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. “With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is […]

August 9, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Aug 2022

Positive trial results for schizophrenia drug, KarTX, from PureTech’s founded entity, Karuna Therapeutics

Positive topline results from a phase 3 trial looking at the effect of a drug to treat schizophrenia were announced today (August 8). Karuna Therapeutics Inc, the founded entity of PureTech Health plc, said results from the EMERGENT-2 trial evaluating the efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults met its primary endpoint and […]

August 8, 2022 - 4 minutesmins - By Liza Laws

Opinion 8 Aug 2022

Building a healthtech industry in Europe to serve patients

By Maryvonne Hiance, president of HealthTech For Care; and Christian Pierret, Former Minister Delegate for Industry The HealthTech For Care endowment fund, launched by France Biotech is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. Europe is just emerging from a health crisis that […]

August 8, 2022 - 5 minutesmins - By External Contributor

News and Trends 8 Aug 2022

Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca

A medication used to treat non-small cell lung carcinomas (NSCLC) with specific mutations has demonstrated a 49% objective response rate (ORR) in patients. AstraZeneca and HUTCHMED announced that TAGRISSO Plus Savolitinib – a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor – was helping patients with high levels of mesenchymal epithelial transition (MET). […]

August 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Dallas College gets $8.8M grant to grow biotech workforce in North Texas

Dallas College has been awarded a U.S. Economic Development Administration grant to help underserved communities access living-wage jobs in biotechnology. The college noted biotech is a sector poised to grow exponentially with the need for additional highly skilled employees in North Texas, according to the latest labor market intelligence. With approximately $8.8 million in funds […]

August 8, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 8 Aug 2022

HUTCHMED drug in colorectal cancer trial meets primary endpoint

A trial to look at the use of a drug targeting refractory metastatic colorectal cancer (CRC) has met its primary endpoint of overall survival (OS) in patients with the disease. China’s HUTCHMED Limited announced today (August 8) that the phase 3 FRESCO-2 trial investigating the use of fruquintinib had met all secondary endpoints too. The […]

August 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Epigenic Therapeutics raises $20M for gene editing technology

Epigenic Therapeutics Co., Ltd., a Chinese biotech gene editing company, has secured $20 million in Series Angel and Pre-A funding. The Series Pre-A funding came from investments by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating. The proceeds will be used to advance the company’s […]

August 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Aug 2022

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

A collaboration between Genmab and BioNTech to develop and commercialize immunotherapies for the treatment of cancer patients has been expanded. Under the expansion announced today (August 5), the companies will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint […]

August 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Allogenic immune cell therapies to be developed as three groups join forces

Three entities have joined forces to develop allogenic immune cell therapies based on a platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs). ElevateBio LLC is a technology-driven company focused on powering transformative cell and gene therapies. It announced recently (August 5) that it has formed a yet-to-be-named company co-founded by […]

August 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Aug 2022

Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia

A phase 2 clinical trial for the treatment of schizophrenia has been accepted by the US Food and Drug Administration (FDA) and a study can now go ahead. Neurocrine Biosciences received the news and informed its partner Sosei Group Corporation. The approval of the study of NBI-1117568 has triggered a $30 million payment to Sosei. […]

August 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Aug 2022

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu. Endogena Therapeutics to start clinical stage with treatment for blindness […]

August 5, 2022

News and Trends 5 Aug 2022

Abivax has approval granted to enroll ulcerative colitis patients in two studies

Patients with moderate to severe ulcerative colitis (UC) can now be enrolled onto two phase 3 induction studies for a biotech company’s lead candidate drug. France-based Abivax SA is a phase 3 clinical stage biotech company that focuses on developing therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer. […]

August 5, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Pfizer and Valneva to start phase 3 Lyme disease vaccine study

Positive trial results for schizophrenia drug, KarTX, from PureTech’s founded entity, Karuna Therapeutics

Building a healthtech industry in Europe to serve patients

Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca

Dallas College gets $8.8M grant to grow biotech workforce in North Texas

HUTCHMED drug in colorectal cancer trial meets primary endpoint

Epigenic Therapeutics raises $20M for gene editing technology

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

Allogenic immune cell therapies to be developed as three groups join forces

Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

Abivax has approval granted to enroll ulcerative colitis patients in two studies

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!